Prothena will cut 63% of its workforce and evaluate a “range of business options.” Elsewhere, Zealand revealed data for a ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...

Prothena Corp shares climbed 5% in after-hours trading on Friday after the company said it expects to reduce its 2025 net ...

Bristol Myers Squibb is teaming up with Prothena in a high-stakes lab dance to tackle Alzheimer’s disease with two ...

Prothena Corporation plc (NASDAQ:PRTA) is among the best NASDAQ stocks under $50 to buy. Roche, a partner of Prothena ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche has announced that it will be advancing its Prothena-partnered investigational Parkinson’s disease (PD) drug ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Chardan slashed the firm’s price target on Prothena Corporation plc (NASDAQ:PRTA) on May 27, lowering it to $18 from $40 while maintaining a Buy rating on the shares. Although the firm is ...

Fintel reports that on May 28, 2025, B of A Securities downgraded their outlook for Prothena (NasdaqGS:PRTA) from Neutral to Underperform. Analyst Price Forecast Suggests 1,045.01% Upside As of ...